Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

61. Common osteoporosis drugs may prevent breast cancer spreading to bone

Common osteoporosis drugs may prevent breast cancer spreading to bone Common osteoporosis drugs may prevent breast cancer spreading to bone Discover Portal Discover Portal Common osteoporosis drugs may prevent breast cancer spreading to bone Published on 13 March 2018 doi: Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However, the overall benefits may

2018 NIHR Dissemination Centre

62. Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain

Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Discover Portal Discover Portal Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Published on 13 December 2016 doi: Injecting cement into osteoporotic spinal fractures within six weeks reduces pain in the first few months and disability six (...) centres. Share your views on the research. Why was this study needed? Worldwide, an estimated 1.4 million people with osteoporosis experience vertebral fractures. Most osteoporotic vertebral fractures are treated conservatively with painkillers, bed rest and mobility exercises as function improves. However, painkillers and prolonged bed rest can both have adverse effects in older people. Vertebroplasty involves injecting special cement into the broken vertebrae to relieve pain and strengthen the bone

2018 NIHR Dissemination Centre

63. Prompts for GPs may improve diagnosis and treatment of osteoporosis

Prompts for GPs may improve diagnosis and treatment of osteoporosis Prompts for GPs may improve diagnosis and treatment of osteoporosis Discover Portal Discover Portal Prompts for GPs may improve diagnosis and treatment of osteoporosis Published on 30 August 2016 doi: Prompts for GPs with education and reminders for patients may improve “guideline consistent behaviour” and diagnosis and treatment of osteoporosis. Similar techniques aimed at improving GP management of other common (...) benefit more. Share your views on the research. Why was this study needed? Musculoskeletal conditions such as osteoporosis, back pain and arthritis are common causes of pain and disability in the UK. One in six adults lives with a chronic musculoskeletal condition. Every year, over 20% of people consult their GP about musculoskeletal problems. Musculoskeletal conditions are a major cause of health system spending. In 2009-10, the NHS spent £4.76 billion in this area; this is more than £13 million

2018 NIHR Dissemination Centre

64. Osteoporosis

Osteoporosis Osteoporosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteoporosis Last reviewed: February 2019 Last updated: October 2018 Summary Asymptomatic until fracture occurs. Diagnosis based on history of prior fragility fracture or low bone mineral density, which is defined as a T-score ≤-2.5. Screening is based on individual risk factors, including female sex, maternal history of fragility fracture (...) /osteoporosis, older age, low body mass index (<20 to 25 kg/m²), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease. Fall prevention is first-line therapy. Bisphosphonates are first-line pharmacological therapy for postmenopausal women and men. In postmenopausal women, oestrogen is considered only for those at high risk for whom non-oestrogen medicines

2018 BMJ Best Practice

65. Prevention and treatment of osteoporosis in women

Prevention and treatment of osteoporosis in women Prevention and treatment of osteoporosis in women | British Menopause Society Search for: Summary consensus statement Prevention and treatment of osteoporosis in women Prevention and treatment of osteoporosis in women 2018-11-09T17:16:44+01:00 Summary The British Menopause Society Council aims to aid health professionals to inform and advise women about post reproductive health. Osteoporosis affects 1 in 3 women. This guidance regarding (...) oestrogen and non oestrogen based treatments for osteoporosis responds to the controversies about the benefits and risks of individual agents. Treatment choice should be based on up to date evidence based information and targeted to individual women’s needs. Summary practice points HRT reduces the risk of both spine and hip as well as other osteoporotic fractures. Oestrogen remains the treatment of choice for osteoporosis prevention in menopausal women, and especially in those with premature ovarian

2018 British Menopause Society

66. Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis

Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis UTCAT3302, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis Clinical Question Can cone beam computed tomography be considered a helpful tool in predicting osteoporosis? Clinical Bottom Line Cone beam computed tomography imaging (...) is a promising technique to predict osteoporosis. For patients who have osteoporosis, CBCT radiodensity can be a predictor of low bone mineral density (BMD). Dentists can use this as a tool to help in early diagnosis and referral of the patient to a physician to manage the case before deterioration. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Guerra/2017 6 studies, 220 patients Systematic review

2017 UTHSCSA Dental School CAT Library

67. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. (PubMed)

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis.In this double-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate (...) in the risedronate group (hazard ratio 0·48, 95% CI 0·32-0·74; p=0·0009). Non-vertebral fragility fractures occurred in 25 (4·0%) patients in the teriparatide group and 38 (6·1%) in the risedronate group (hazard ratio 0·66; 95% CI 0·39-1·10; p=0·10).Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate.Lilly.Copyright © 2018 Elsevier Ltd. All rights reserved.

2017 Lancet

68. Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis (PubMed)

Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis Osteoporosis is a common condition with serious consequences because of fractures. Despite availability of treatments to reduce fracture risk, there is a large osteoporosis treatment gap that has reached crisis proportions. There are too few specialists to provide services for patients who need them. Bone Health Extension for Community Health Care Outcomes (TeleECHO) is a strategy using real-time ongoing (...) -confidence in 20 domains of osteoporosis care showed substantial improvement with the ECHO intervention (P = 0.005). Bone Health TeleECHO can contribute to mitigating the crisis in osteoporosis care by leveraging scarce resources, providing motivated practitioners with skills to provide better skeletal health care, closer to home, with greater convenience, and lower cost than referral to a specialty center. Bone Health TeleECHO can be replicated in any location worldwide to reach anyone with Internet

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

69. Prevention of osteoporosis in female students based on the Orem self-care model (PubMed)

Prevention of osteoporosis in female students based on the Orem self-care model The World Health Organization has introduced osteoporosis as the fourth main enemy of mankind. Self care has served as a new trend in health care.Educational intervention for osteoporosis related preventive self care in female university students using the Orem model.This study is a controlled filed trial, carried out with female students of Islamic Azad University, Shahrekord Branch, Iran, from October 28, 2014 (...) to November 15, 2016. Two-stage random stratified sampling was performed and the data were collected through a validated questionnaire developed by the researcher for osteoporosis preventive self-care based on the Orem model. The intervention group received education about osteoporosis preventive self-care through two months training, as per the dimensions in the Orem model. For statistical analysis, independent-samples t-test and paired t-test were used in SPSS version 23.As revealed, mean scores

Full Text available with Trip Pro

2017 Electronic physician

70. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. (PubMed)

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption.We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate (...) observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed.In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed

Full Text available with Trip Pro

2017 NEJM

71. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP).We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group (...) GC users.Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D

Full Text available with Trip Pro

2017 EvidenceUpdates

72. Osteoporosis. (PubMed)

Osteoporosis. Osteoporosis is a common systemic skeletal disorder resulting in bone fragility and increased fracture risk. However, management of osteoporosis and fracture prevention strategies are often not addressed by primary care clinicians, even in older patients with recent fractures. Evidence-based screening strategies will improve identification of patients who are most likely to benefit from drug treatment to prevent fracture. In addition, careful consideration of when pharmacotherapy

2017 Annals of Internal Medicine

73. Bisphosphonates for treating osteoporosis

Bisphosphonates for treating osteoporosis Bisphosphonates for treating Bisphosphonates for treating osteoporosis osteoporosis T echnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Bisphosphonates for treating osteoporosis (TA464) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 25Contents Contents 1 Recommendations 4 2 The technologies 7 3 Committee discussion 9 Nature of the condition 9 Clinical management of the condition 9 Assessing

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

74. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. (PubMed)

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women with postmenopausal osteoporosis transitioning from (...) bisphosphonate therapy.This randomised, phase 3, open-label, active-controlled study was done at 46 sites in North America, Latin America, and Europe. We enrolled women (aged ≥55 to ≤90 years) with postmenopausal osteoporosis who had taken an oral bisphosphonate for at least 3 years before screening and alendronate the year before screening; an areal BMD T score of -2·5 or lower at the total hip, femoral neck, or lumbar spine; and a history of fracture. Patients were randomly assigned (1:1) via

2017 Lancet

75. Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value

Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value ©Institute for Clinical and Economic Review, 2017 Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value Evidence Report June 16, 2017 Prepared for Note: When our process began, ICER expected FDA approval of two new anabolic agents for osteoporosis in the first half of 2017. On May 21, 2017, Amgen and UCB issued a press release with topline results from the ARCH trial (...) that include romosozumab. However, we have elected to retain the summary of the romosozumab trial results as well as the newly available summary results of the ARCH trial because they provide important contextual information to frame the larger discussion of the role of anabolic therapies in preventing osteoporotic fractures. ©Institute for Clinical and Economic Review, 2017 Page i Evidence Report – Anabolic Therapies for Osteoporosis ICER Staff and Consultants University of Washington School of Pharmacy

2017 California Technology Assessment Forum

76. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP).We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group (...) GC users.Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D

Full Text available with Trip Pro

2017 EvidenceUpdates

77. Nutrition and osteoporosis prevention for the orthopaedic surgeon: A wholefoods approach (PubMed)

Nutrition and osteoporosis prevention for the orthopaedic surgeon: A wholefoods approach Osteoporosis is a prevalent and debilitating condition with no signs of subsiding. Rising numbers of people consuming nutrient-poor diets coupled with ageing populations and sedentary lifestyles appear to be the main drivers behind this.While the nutrients calcium and vitamin D have received most attention, there is growing evidence that wholefoods and other micronutrients have roles to play in primary (...) and potentially secondary osteoporosis prevention.Until recently, calcium and vitamin D were regarded as the main nutrients essential to bone health but now there are emerging roles for iron, copper and selenium, among others.Fruit and vegetables are still not being eaten in adequate amounts and yet contain micronutrients and phytochemicals useful for bone remodelling (bone formation and resorption) and are essential for reducing inflammation and oxidative stress.There is emerging evidence that dried fruits

Full Text available with Trip Pro

2017 EFORT open reviews

78. Bindex for people with suspected osteoporosis

Bindex for people with suspected osteoporosis Binde Bindex for in x for inv vestigating suspected osteoporosis estigating suspected osteoporosis Medtech innovation briefing Published: 31 May 2017 nice.org.uk/guidance/mib106 pathways Summary Summary The technology technology described in this briefing is Bindex, a portable pulse-echo ultrasound device used to help make decisions on the investigation and treatment of osteoporosis. The inno innovativ vative aspects e aspects are that it is pocket (...) sized and can be connected to and used with any laptop or desktop computer's USB socket. Unlike other quantitative ultrasound that measures sound speed and attenuation in the heel, Bindex makes measurements of the tibia applying thresholds of 90% sensitivity and specificity compared with axial dual-energy X-ray absorptiometry (DXA), to help with decisions on further tests and treatment for osteoporosis. The intended place in ther place in therap apy y would be to use Bindex alongside current

2017 National Institute for Health and Clinical Excellence - Advice

79. Abaloparatide (Tymlos) Subcutaneous Injection - osteoporosis in postmenopausal women

Abaloparatide (Tymlos) Subcutaneous Injection - osteoporosis in postmenopausal women Tymlos Subcutaneous Injection U.S. Department of Health and Human Services Search FDA Submit search Tymlos Subcutaneous Injection DUPIXENT Company: Radius Health, Inc. Application No.: 208743 Approval Date: 04/28/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2017 FDA - Drug Approval Package

80. Romosozumab for osteoporosis in men

Romosozumab for osteoporosis in men Romosozumab for osteoporosis in men | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Romosozumab (...) for osteoporosis in men Romosozumab for osteoporosis in men May 2017 Romosozumab arose from a genetic discovery that revealed the body’s own natural ability to increase bone strength. It is a treatment which aims to block the activity of the protein sclerostin. This diminishes bone breakdown and removal and stimulates bone formation, thereby increasing bone strength. The effectiveness and safety of romosozumab for the treatment of osteoporosis in men has been studied in a phase III clinical trial. The study

2017 NIHR Innovation Observatory